Acquisition of CDMO Lusomedicamenta Sociedade Técnica Farmacêutica S.A. (PT) by Recipharm AB (SE) — Enterprise value SEK 1 billion

Carnegie acted as financial adviser to Recipharm in the acquisition of Lusomedicamenta. Recipharm provides contract manufacturing and development services for other pharmaceutical companies. Lusomedicamenta is primarily a CDMO specialised in the development and manufacture of solid, liquid and semi-solid dose forms as well as sterile ophthalmic products. November 2014.